Racial Disparities in Multiple Myeloma Diagnosis and Treatment
Uncovering Delayed Diagnoses
For over a year, Diane Hunter, 72, experienced vague symptoms including spine and hip pain, nausea, exhaustion, and frequent urination. Initially dismissed by her primary care physician as signs of aging, her condition worsened until she was eventually rushed to the emergency room. It was there that a doctor suggested she might have multiple myeloma, a blood cancer that affects plasma cells in the bstart marrow, leading to a reduction of healthy blood cells and damaging bstarts.
Hunter’s experience is not unique; it highlights a troubling trend of delayed diagnoses, especially among African Americans who often face additional societal barriers, including limited access to healthcare servstarts and insurance. Multiple studies have shown that these factors contribute significantly to mortality rates, as the disease has a higher fatality rate among Black patients compared to their white counterparts.
The Diagnostic Journey
Despite her endocrinologist’s recommendation to see a hematologist due to high protein levels in her blood, Hunter’s previous doctor dismissed this and refused to order necessary tests. Frustrated by the lack of action, she sought care from a new physician who diagnosed her with multiple myeloma. Monique Hartley-Brown, a researcher at Dana-Farber Cancer Institute, noted, “On average, patients see their primary doctor three times before receiving an accurate diagnosis,” emphasizing that the delay is often more pronounced for Black Americans.
As the disease can cause significant complications like severe anemia, fatigue, and kidney issues, timely diagnosis is critical.
Disparities in Treatment Access
Racial disparities continue even after diagnosis. According to the Multiple Myeloma Research Foundation, Black and Hispanic patients are statistically less likely to have access to the latest therapies. An analysis conducted in 2022 found that only 4% of participants in clinical trials for myeloma drugs were Black, while they represent approximately 20% of those affected by the disease.
The current landscape of cancer research is facing challenges, exacerbated by potential federal cuts to cancer research funding. Michael Andreini, CEO of the Multiple Myeloma Research Foundation, commented on the implications, noting that funding for myeloma research lags behind its prevalence and that any funding cuts jeopardize future innovations.
Challenges in Diagnosing Multiple Myeloma
Diagnosing multiple myeloma remains challenging, as it typically presents symptoms that can be mistaken for normal aging, especially in patients over 65. For example, Jim Washington, a 61-year-old from Charlotte, North Carolina, initially attributed his severe hip pain to injury, only to later learn he had multiple myeloma after rapid referrals from a concierge doctor and subsequent tests.
Washington underwent high-dose chemotherapy followed by an autologous stem cell transplant, ultimately achieving a clean bill of health. His experience underscores the importance of timely medical intervention and the role that access to healthcare plays in patient outcomes.
Innovations in Treatment
Despite these disparities, advancements in treatment provide hope. The FDA approved CAR T-cell therapy for multiple myeloma in 2021, marking a significant mileststart in treatment options. This method involves modifying a patient’s T cells to attack cancer cells more effectively. Washington benefited from this groundbreaking treatment, showcasing the potential for recovery.
Hunter, who achieved remission after her own treatment journey, works as a support group leader and advocate, offering hope to others affected by multiple myeloma. “The word ‘cure’ is now being heard,” she noted, emphasizing the progress made over the past few years in understanding and treating the disease.
Conclusion
As research into multiple myeloma progresses, addressing the barriers that contribute to racial disparities in diagnosis and treatment remains crucial. Advocacy and increased awareness may improve access to care and timely treatment, potentially shifting the outlook for many who face this challenging diagnosis.
KFF Health News is committed to in-depth journalism about health issues, offering insights into ongoing challenges and developments in medical care and policy.